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Abstract: Vascular complications of diabetes mellitus are an important issue for all clinicians involved
in the management of this complex pathology. Although many therapeutic advances have been
reached, peripheral arterial disease is still an unsolved problem that each year compromises the
quality of life and life span of affected patients. Oftentimes, patients, after ineffective attempts of
revascularization, undergo greater amputations. At the moment, there is no effective and definitive
treatment available. In this scenario, the therapeutic use of stem cells could be an interesting option.
The aim of the present review is to gather all the best available evidence in this regard and to define a
new role of the stem cells therapy in this field, from biomarker to possible therapeutic target.
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1. Background
Atherosclerosis is the leading cause of death worldwide, with myocardial infarction and stroke
accounting for almost 15 million deaths in 2015 [1]. Lower limb peripheral artery disease (LL-PAD)
belongs to the pathological spectrum of atherosclerosis and is an important cause of death and disability,
with a prevalence ranging between 3% and 10% in the general population and as high as 15% to
20% in persons aged >70 years [2–4]. This population has an increased risk of cardiovascular and
cerebrovascular accidents, and up to 10% of them will progress to critical limb ischemia (CLI), which is
the final stage of LL-PAD. Such figure corresponds to and incidence of 500–1000 per million in the
developed world. As prevalence of diabetes mellitus increases, especially in developing countries, and
with the ageing of the population, these figures are likely to rise in the foreseeable future. Patients
with CLI, in turn, have a reduced life expectancy and a significant morbidity, due to recurrent soft
tissue infections, difficult-to-treat ischemic pain, reduced mobility and limb amputation. Despite
considerable improvement in the pharmacological therapy and the availability of endovascular and
surgical treatment for CLI, about 50% of patients with CLI undergoing treatment will be dead or
amputated at a one-year follow-up [5]. Thus, while effective, there is still an unmet therapeutic need in
the treatment of patients with critical limb ischemia. In the last two decades, therapeutic angiogenesis
has emerged as a new possibility in the management of CLI. Therapeutic angiogenesis refers to the
use of directly inoculated angiogenetic factors, genes or cells in the ischemic limb in order to induce
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or improve the physiological process of collateral vessel formation. While tempting, this option is
still unavailable for routine clinical use. The aim of this review is to offer an overview of cell-based
therapeutic angiogenesis, to summarize the results of the main clinical trials in this field, to highlight
the gap in the evidence that prevents this strategy from being routinely used.
2. Overview of Stem Cells
Almost all stem cells can be classified according to their degree of potency and the related site of
harvesting. Thus, each stem cell population belongs to one of four classes:
• Totipotent stem cells, which are able, in principle, to give rise to a complete individual; embryonal
cells, up to the four-blastomeres stage, belong to this group [6,7];
• Pluripotent stem cells, which are able to differentiate into the three embryonal sheaths but not
into extra-embryonal structure; embryonal stem cells belong to this group [8];
• Multipotent stem cells, which are able to differentiate into a restricted number of cell types; adult
(also called somatic) stem cells, which are cells whose role is the renewal of self-renewing tissues,
belong to this group;
• Unipotent stem cells, which are able to differentiate into a single cell type; for example,
lineage-committed hematopoietic cells belong to this type.
Totipotent and pluripotent stem cells are, potentially, the ideal source for tissue engineering.
However, ethical and clinical concerns limit their use and, while an area of active research, they will
probably not be available at the bedside in the near future. Conversely, multipotent stem cells are
widely available from multiple adult tissues and, unlike unipotent stem cells, have sufficient plasticity
for tissue repairing. Multipotent stem cells harvested from bone marrow and from adipose tissue have
actually been tested for therapeutic angiogenesis in multiple clinical trials (Table S1).
Asahara et al. first demonstrated that hematopoietic stem cells (HSC) can differentiate into
endothelial cells and can sustain angiogenesis in adult individuals [9]. Bone marrow contains also a
population of non-hematopoietic stem cells, which present a spindle-shaped structure and are able to
give rise to mature mesenchymal tissues (cartilage, bone, adipose tissue, connective tissue) in culture
conditions, defined mesenchymal stem cells [10]. Mesenchymal stem cells (MSCs) have been isolated
from multiple adult tissues, including bone marrow and adipose tissue [11–14], and are thought
of as a cell population with interesting characteristics, including an immunoprivileged status, the
ability to secrete paracrine factors with angiogenetic, immunomodulatory and anti-inflammatory
properties [15,16]. They have been used in treating graft-versus-host disease [17] and are a promising
tool for autoimmune disease. Moreover, they seem to be able to both differentiate into endothelial
cells and to promote angiogenesis indirectly via two mechanisms: paracrine stimulation of endothelial
progenitor cells and direct participation in the formation of the mesenchymal scaffold required for
effective vessel formation [18–22]. Currently, there is not a single surface marker which can be used for
mesenchymal cell identification and such cells have been traditionally been defined by their in vitro
properties (spindle shape, plastic-adherence, ability to differentiate into chondroblasts, osteoblasts
and adipocytes). In 2006, the International Society of Stem Cell Therapy has issued a minimum set of
criteria for mesenchymal stem cell definition: apart from the said characteristics, they must not express
hematopoietic or endothelial commitment markers (CD45, CD34, CD14 or CD11b, CD79alpha or CD19
and HLA-DR) and they must express CD73, CD105 and CD90 [23].
Given the above considerations, the availability and relative ease of collection, bone marrow stem
cells have been the most investigated type of stem cells for therapeutic angiogenesis (Figure 1). To
understand clinical trials on this topic, one must keep in mind the characteristics that distinguish each
trial, which can be summarized as follows:
1. Specific stem cell population: some trials have used hematopoietic stem cells (based on
the assumption that these cells differentiate into endothelial cells), bone-marrow-derived
mesenchymal stem cells (based on the fact that these cells are able to differentiate, in vitro,
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into endothelial cells and are able to give rise to pericytes, which are the required scaffold
for newly-formed vessels and, moreover, are able to secrete paracrine factors that form the
intracellular milieu for angiogenesis) or a mixed population;
2. Harvesting mode: most trials have used direct bone-marrow aspiration, while a limited number
of trials have used circulating HSCs, after mobilization by colony-stimulating factors;
3. Possible in vitro expansion of harvested cells (especially for MSCs);
4. Exact immunophenotypical characterization of cells;
5. Phase (most studies are phase 1-2 studies, while only a single published study is a phase 3 trial).
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more recently, myoblasts populations with a uniform and known expression of VEGF have been 
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nude mice [41]. This approach has also been applied to MSCs. For example, Fierro et al. induced 
expression of platelet derived growth factor subunit B (PDGF-B), VEGF, basic fibroblast growth 
factor (bFGF), transforming growth factor-β (TGF-β) in marrow-derived MSCs, showing that 
different induced expression of the aforementioned factors could alter the fate of MSCs after 
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effective and safe in an animal model [43] and could be efficiently produced according to Good 
Manufacturing Practices [44]. Stable and uniform VEGF expression has been obtained also in 
adipose-derived mesenchymal stem cells (ASC), which proved effective in slowing decline in 
ejection fraction of murine heart after myocardial infarction [45,46].Further combination are possible 
by combining gene transfection with systemic, local or pre-injection treatment with specific soluble 
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As MSCs tend to home in sites of hypoxic injury, can differentiate into pericytes and secrete 
several growth factors, gene-transfer-enhanced MSCs could be the missing link between gene- and 
cell-based therapies. However, such cells have been generated by retroviral or lentiviral vectors. 
Thus, immunogenicity of the final product as well as the risk of potential insertional mutagenesis 
remain concerning. Plasmid gene delivery is less efficient than viral gene delivery but, in principle, 
safer. Moreover, plasmids may be lost during in vivo replication of injected cells. To address the first 
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Besides their direct role in angiogenesis, ste cells ay be used as gene therapy vectors. iven
its pivotal role in post-natal angiogenesis and in tu oral angiogenesis [24], vascular endothelial
gro th factor (VE F) ad inistration has gained a lot of interest as a potential angiogenetic therapy in
different ischemic states [25], with partially disappointing results [26–33]. The lack of efficacy of VEGF
therapy is probably linked to the fact that normal or aberrant vascular growth is strictly dependent in
microenvironmental VEGF concentration and on sufficient duration of VEGF stimulation to spurring
vessels; thus, it cannot be adequately controlled by systemic administration of either the protein itself
or VEGF gene-containing plasmids [34–39]. Stem cells may be a key to overcome this limitation.
For example, VEGF expression has been induced in myoblasts [40] and, more recently, myoblasts
populations with a uniform and known expression of VEGF have been isolated and shown to induce
angiogenesis without giving rise to aberrant vascular structure in nude mice [41]. This approach has also
been applied to MSCs. For example, Fierro et al. induced expression of platelet derived growth factor
subunit B (PDGF-B), VEGF, basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-β)
in marrow-derived MSCs, showing that different induced expression of the aforementioned factors
could alter the fate of MSCs after implantation or their effect on angiogenesis [42]. They also showed
that such a population could be effective and safe in an animal model [43] and could be efficiently
produced according to Good Manufacturing Practices [44]. Stable and uniform VEGF expression
has been obtained also in adipose-derived mesenchymal stem cells (ASC), which proved effective
in slowing decline in ejection fraction of murine heart after myocardial infarction [45,46].Further
combination are possible by combining gene transfection with systemic, local or pre-injection treatment
with specific soluble factors [47].
As MSCs tend to home in sites of hypoxic injury, can differentiate into pericytes and secrete
several growth factors, gene-transfer-enhanced MSCs could be the missing link between gene- and
cell-based therapies. However, such cells have been generated by retroviral or lentiviral vectors. Thus,
immunogenicity of the final product as well as the risk of potential insertional mutagenesis remain
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concerning. Plasmid gene delivery is less efficient than viral gene delivery but, in principle, safer.
Moreover, plasmids may be lost during in vivo replication of injected cells. To address the first point,
co-expression of the desired gene with a marker gene could be used to select the actually transfected
population out of a pool of cells which have undergone a plasmid transfection procedure. Park et al.
have shown that co-expression of VEGF with the enhanced green fluorescent protein (EGFP) allowed
the enrichment of a starting population of MSCs via flow cytometry. Such enriched population has
proved effective in the animal model at 21 days [48]. It is worth noticing that Park et al. [48] point out
that the ability of MSCs to create an angiogenetic environment makes them the ideal candidate for
combined cell/gene therapy in ischemic disease.
As PAD is a particularly common in diabetic patients, one question is whether impaired metabolic
pathways lead to a decreased angiogenetic capacity of diabetic patients’ stem cells. In fact, together
with accelerated atherosclerosis, impaired angiogenesis has been called into question to explain the
increased susceptibility of this population to vascular disease [49–54]. Such impaired angiogenesis
seems, at least in part, to be linked to reduced response to VEGF by circulating endothelial progenitor
cells [55–57], to reduced absolute circulating number of endothelial progenitor cells and to stem cells
dysfunction [58–61]. Diabetes mellitus may, furthermore, be deleterious also for MSCs [62]. Based
on these premises, it has been postulated that pretreatment with specific signaling proteins could
alter the functionality of stem cells to induce a more clinically efficient phenotype. Thus, Amin
et al. [63] stimulated BM-derived MSCs from diabetic mice with epidermal growth factor before
injection into ischemic hindlimbs. Pre-treatment with EGF resulted in accelerated angiogenesis
compared with diabetic mice who received non-pretreated MSCs and this effect was probably due to
increased expression of phosphorylated VEGF-R and Akt in the former. In vitro, they observed and
increased adhesion and migration of pre-treated cells compared to non-pretreated cells. In keeping
with these results, our group has shown that HMBG-1, albeit at supraphysiological concentration, is
capable of inducing vascular differentiation of stem cells and that this effect is dependent on the VEGF
pathway [64], while another group has shown that IL-8 may be another potential candidate to enhance
angiogenetic capabilities of stem cells [65]. Given their immunomodulatory properties, allogenic MSCs
may be an alternative both to overcome the diabetes-induced dysfunction of autologous MSCs and to
allow for more economically efficient source of MSCs [66,67].
3. Human Trials of Stem Cells Therapy
In 2002, Tateishi-Yuyama et al. [68] performed a landmark trial on the use of a mixed population of
bone-marrow-derived CD34+ and CD34- cells for no-option critical limb ischemia. In their study, they
performed both a pilot phase and a subsequent study with formal sample size assessment. Cells did not
undergo an in-vitro expansion phase and were only sorted and concentrated before limb implantation.
They found a marginal increase in ankle/brachial index (ABI) values in treated limbs compared with
untreated limbs (+0.1). However, they found a noteworthy increase in TcPO2 (+12.00 mm Hg compared
with saline-treated limbs, with an overall absolute increase of 16.6 mm Hg compared to baseline). 16
out of 20 patients in the treatment group experienced complete resolution of rest pain, versus only
3 out of 20 in the control group. Magnetic resonance angiography (MRA) showed an increase in
collateral vessels in the treatment group compared with the control group, consistent with the clinical
improvement. A major strength of this study is the blinding of all investigators prior to treatment
assignment of patients. After randomization, authors report that blinding was maintained for all the
involved personnel, except for each center principal investigator. Obviously, a complete blinding up to
and including outcome assessment for all involved personnel, including principal investigators, would
have made results more reliable. Moreover, there was a “limb-level” randomization, which entailed
that in each patient, a single limb was used as a treatment limb while the other served as control. While
this approach made the two groups more comparable in term of baseline characteristics, it prevented
the study to be able to assess possible systemic adverse events or benefits. The small increase in ABI
with a proportionally bigger increase in TcPO2 may be explained by the fact that neo-angiogenesis is
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expected to occur at the smaller vessel level. That is, large vessel patency is unlikely to be affected by
stem cells implantation, thus explaining small increases in ABI values, while small vessel collaterals
may support distal limb oxygenation even without a significant increase in blood pressure. Moreover,
in control group limb peripheral blood mononuclear cells were implanted, which may have exerted
some potentially beneficial effect, thus mitigating the observed effect of stem cells therapy. It should
also be noted that patients enrolled in this study had an ABI below 0.6, thus representing a particularly
advanced form of PAD. Aside from clinical findings, authors also performed molecular analysis on the
used cells. It is noteworthy that CD34− cells (i.e., cells that were not hematopoietic progenitors, HSC)
had the highest expression of mRNAs codifying for bFGF, angiopoietin-1 and VEGF, whereas CD34+
cells showed more mRNAs codifying for the respective receptors, thus supporting the concept that
marrow-derived MSCs are necessary to support HSCs angiogenesis.
Those encouraging results were partly replicated in 2005 by Huang et al. [69]. These authors
focused exclusively on diabetic patients, both type 1 and type 2, and used peripheral blood mononuclear
cells after mobilization via administration of granulocyte colony stimulating factor (G-CSF). While they
obtained an impressive improvement in treated patients versus control patients, they did not report
about randomization procedure, and the study was performed open label. Moreover, treated group
both received G-CSF and intravenous heparin, while the control group received prostaglandin E1
infusion, thus raising the possibility that the effect seen may be partly attributable to those differential
treatment. Additionally, they did not perform a formal sample size calculation and did not specify
the statistical power of the study. It is worth noticing that these authors reported improvement in
glycemic control in treated subjects. They assume that this effect may be due to an action of stem
cells on pancreatic β-cells; however, taking into account the above consideration, this may also be an
indirect evidence of performance bias.
Both those studies used mixed bone-marrow cells populations. Thus, they were not designed
to evaluate whether mesenchymal stem cells or mixed mononuclear cells were responsible for the
reported clinical benefit. In 2011, Lu et al. [70] performed a three-arms study to both evaluate
whether stem cells therapy is effective in CLI and to evaluate the relative benefit of mixed bone
marrow population and mesenchymal stem cells. In their study, they separately compared both a
mixed population of bone-marrow derived mononuclear cells (BM-MNCs) and sorted bone-marrow
mesenchymal stem cells (BM-MSCs) with a placebo group of limbs, in which only normal saline was
injected. BM-MSCs were sorted via Ficoll gradient centrifugation from a 30 mL marrow aspirate and
then expanded in vitro before injection, while BM-MNCs did not undergo expansion. They showed
clinical benefit upon control for both the treatments, with a more marked increase for limbs receiving
mesenchymal stem cells. This benefit included a 100% ulcer healing and no amputation in the treated
limbs. This study represents a landmark trial in cell therapy for several reasons. First, this is the
first study to directly compare mononuclear cells and mesenchymal stem cells; secondly, the MSCs
underwent immunophenotypical testing and complied with the IFSCT criteria for mesenchymal stem
cells definition; third, this study showed that in vitro expanded MSCs did not induce adverse event at a
24-week follow-up. Moreover, this study showed that MSCs treatment resulted in greater improvement
in clinical outcomes than mixed mononuclear cells. Aside from clinical outcomes, the authors also
showed that MSCs produce a greater amount of angiopoietic factors (specifically VEGF, angiopoietin-1
and bFGF) than MNCs and this difference is increased in hypoxic conditions. As hematopoietic stem
cells (CD34+) are known to physiologically circulate and take part in angiogenesis, this study may
support the idea that the bottleneck in angiogenesis in CLI patients is represented by the availability
of MSCs. Thus, the higher number of MSCs injected in BM-MSCs treated patients may explain the
greater improvement in these subjects. From a methodological point of view, this study is reported to
be randomized, double-blind and single center. While randomization has been conducted with two
independent randomization tables (one to assign patients to MSC or MNC group and the other to assign
each limb of each patient to treatment or to control group), how blinding was attained and maintained
has not been reported. Moreover, MSCs treatment required the aspiration of a far smaller amount
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of marrow blood compared to MNCs treatment (30 vs. 300 mL). However, the in vitro expansion
procedure is time-consuming and may represent a limit in routine implementation of their technique.
In 2012, Ozturk et al. [71] replicated the results by Huang et al. [69]. They enrolled 20 treatment
patients to be injected with GM-CSF mobilized peripheral blood CD34+ cells and 20 control patients,
showing a small but meaningful difference in clinical parameters after 12 weeks of follow-up. Of note,
they did not retransplant patients after 40 days if required (like in the Huang’s paper). However, the
small sample size, the single center and open label nature of the study make their result insufficient for
clinical use. Moreover, the management of control group, apart for best medical therapy, is unclear. Of
note, control patients, unlike treated patients, did not receive GM-CSF or heparin.
While other smaller studies have confirmed these results, they are all pilot studies, with small
sample size or inadequate blinding [72,73]. However, In the same year, the RESTORE-CLI, the
first multicenter and sponsor-initiated study has been published [74,75]. In this study, a cellular
product named Ixymielocel-T, crafted from each patient’s bone marrow stem cells, has been used.
Ixymielocel-T was a mixed population of MSCs and HSCs (CD90+ the former, CD34+ the latter) which
underwent expansion by a proprietary procedure. As reported, only MSCs (i.e. the CD90+ fraction
of bone-marrow aspirate) and macrophage-committed HSCs (CD14+) underwent in vitro expansion.
Thus, Ixymielocel-T may be thought of as a variant of in vitro expanded MSCs (given that expanded
CD90+ cells were the major constituent of the final product). This was a phase 2 study and, as such, was
designed to evaluate safety and was not powered to evaluate efficacy over placebo. However, this is the
first multicenter study, with 18 centers across USA and with reliable blinding procedures reported. It
enrolled CLI patients who were not amenable to surgical or endovascular revascularization procedures
and, apart from safety, showed efficacy of the cell therapy on a composite endpoint of treatment failures
(defined as the time to first occurrence of a treatment failure, which, in turn, consisted of the composite
of major amputation, doubling of the ulcers area, de novo gangrene and all-cause mortality). The
study did not reach statistical significance on the endpoint of amputation-free survival. Again, the
RESTORE-CLI was a phase 2 trial, which had as strengths, its multicenter, randomized and double
blinded nature and which gave encouraging results. It is worth noticing that Ixymielocel-T showed
benefits also in patients with cardiac failure [76,77]. The RESTORE-CLI and the above-mentioned
TACT studies were the only ones to enroll only CLI patients without surgical options.
Subsequently, there has been an increased interest on the use of MSCs in CLI. Two studies
evaluated the efficacy of MSCs therapy in CLI. The first study [78], while performed with the declared
intent of using exclusively MSCs, specifically peripheral blood MSCs after mobilization with G-CSF,
critically, did not specify how MSCs were sorted nor any immunophenotyping. However, it showed
impressive results (with no amputation in the treatment group after three months, versus a 50%
amputation rate in the control group). The second study was a phase 1 trial [79] which, for the first
time, used allogenic stem cells. Investigators performed immunophenotyping on the stem cells, so to
satisfy ISCT criteria for MSCs and did not use immunosuppressive drugs (notwithstanding the fact
that donors were not HLA-matched to recipients), thus leveraging the immunomodulatory properties
of MSCs. This study was also a multicenter study, with central randomization. Being a phase 1 trial,
there was no blinding. The authors reported, again, impressive results with respect to ABI and rest
pain, but with no significant difference in amputation rates. Again, the small sample size and the phase
1 nature of this study may have prevented it from showing statistically meaningful differences on
this clinical endpoint. However, the use of allogenic MSCs without the need for HLA matching nor
immunosuppressive therapy is intriguing and may pave the way to off-the-shelf MSCs products which
may be able to overcome the limitation of the long time required for patient-specific preparations.
Another interesting development of stem cells therapy is the possibility to use MSCs not derived
from bone marrow. As said above, MSCs are found in many different tissue types and they are
particularly abundant in adipose tissue. Thus, adipose tissue may represent a source of abundant,
readily available stem cells, without the need for bone marrow aspiration. Joining this concept with that
of allogenic stem cells transplantation may pave the way for liposuction-derived off-the-shelf cellular
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products, without the need of bone marrow donation or the need for patient-specific preparation. The
use of autologous adipose tissue-derived MSCs has been tested in a phase 1 trial [80] which showed
overall safety of this approach, with a putative benefit (seen only on wound size). It is worth noticing
that meta-analysis on the use of stem cell therapy in CLI have confirmed the benefits observed in
single studies [81,82], but pointing out methodological issues which limit their applicability to clinical
practice [83].
4. Conclusions
The therapeutic use of stem cells represents an interesting new direction in the management of
vascular complications of diabetes mellitus and, in general, of peripheral artery disease. In our opinion,
several issues should be addressed before cell therapy may be part of routine clinical practice. First,
while none of the studies reviewed in our article showed potential adverse effect of stem cell therapy, it
is clear that none of these studies was large enough to detect potentially rare adverse event. Moreover,
very long follow-up would be needed to exclude the possibility of tumorigenesis by implanted stem
cells. However, it is worth noticing that no such potential concern has been raised by any of the
reviewed studies. Second, it is not clear whether administration of stem cells at an earlier stage of
disease could be more beneficial. All the studies reviewed in this paper have enrolled patients with
clinically evident CLI. Furthermore, CLI is known to be the end stage of lower limb atherosclerosis.
Thus, once longer follow-up on CLI patients will be available, there is need of further research to clarify
whether earlier use of stem cell therapy can affect the course of disease.
We also focused on the possible pre-implantation treatment of stem cells with various growth factors
to improve their angiogenetic properties. In principle, a better understanding of the atherosclerotic
process could lead to personalized treatment for different group of patients. For example, the use of
specific injected genes or different growth factors for pre-treatment of stem cells could be based on
specific phenotypical characteristics of the patient, such as the presence or not of diabetes, a history of
smoking or specific circulating markers.
Thus far, however, the most important unmet need in the field of cell therapy for PAD is the
lack of methodologically sound phase 3 randomized controlled trials to ultimately show clinically
significant benefit of stem cell therapy.
Although many points are still unclear and additional data are needed, it is important that this
field be explored with following studies to design a new therapeutic approach available in this scenario.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/9/2233/
s1.
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